DDrare: Database of Drug Development for Rare Diseases

107. 若年性特発性関節炎［全身型若年性特発性関節炎（~2018.3）］
［臨床試験数：151，薬物数：75（DrugBank：13），標的遺伝子数：16，標的パスウェイ数：90］

Searched query = "Juvenile idiopathic arthritis", "Systemic juvenile idiopathic arthritis", "Systemic-onset juvenile idiopathic arthritis", "JIA", "SJIA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACTEMRA; ACZ885; ACZ885 150 mg (Canakinumab); ACZ885 Drug Substance; ACZ885G; ANAKINRA; APD421; Abatacept; Actemra; Actemra, MRA; Anakinra; Anakinra / kineret; BARICITINIB; Baricitinib; CANAKINUMAB; CCP-690-550-10; CP; CP-690,550-10; CSs; Canakinumab; Corticosteroids; EMAPALUMAB; Emapalumab; Fully human anti-interferon gamma monoclonal antibody; Heparin; IL-6 receptor inhibitor, recombinant humanized monoclonal antibody; ILARIS; ITF2357; Ilaris; In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Interferon Gamma; KINERET*SC 7SIR 100MG 0,67ML; Kineret; Kineret® or anakinra; LY3009104; Ly3009104; MRA; MRA (Actemra); MRA (tocilizumab); MRA(Tocilizumab); MRA, Actemra; MTX; Methotrexate; NI-0501; NSAIDs; Non-steroidal anti-inflammatory drugs (NSAIDs); Null; Olumiant; Pneumo23; REGN88; RIL-1RA; RO4877533 (TCZ); Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R; Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class; Rilonacept; Rilonacept (IL-1 Trap); Ro 487-7533/F10-04; RoActemra; Roactemra; SAR153191; SAR153191 (REGN88); SARILUMAB; Sarilumab; Sarilumab SAR153191 (REGN88); TOCILIZUMAB; TOCILIZUMAB SC; TOFACITINIB CITRATE; Tocilizumab; Tocilizumab Roche; Tocilizumab SC; Tocilizumab [RoActemra/Actemra]; Tofacitinib; Tofacitinib citrate; Tofacitinibe citrate

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00534495 (ClinicalTrials.gov)	November 2008	24/9/2007	Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults	Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)	Juvenile Idiopathic Arthritis	Biological: Rilonacept	Montefiore Medical Center	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Months	19 Years	All	71	Phase 2	United States
2	NCT01803321 (ClinicalTrials.gov)	November 2005	28/2/2013	Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)	A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)	Systemic Juvenile Idiopathic Arthritis	Drug: rilonacept (IL-1 Trap);Other: Placebo	Regeneron Pharmaceuticals	NULL	Completed	4 Years	20 Years	Both	24	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00534495
(ClinicalTrials.gov)

November 2008

24/9/2007

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults

Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)

Juvenile Idiopathic Arthritis

Biological: Rilonacept

Montefiore Medical Center

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

18 Months

19 Years

All

Phase 2

United States

NCT01803321
(ClinicalTrials.gov)

November 2005

28/2/2013

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Systemic Juvenile Idiopathic Arthritis

Drug: rilonacept (IL-1 Trap);Other: Placebo

Regeneron Pharmaceuticals

NULL

Completed

4 Years

20 Years

Both

Phase 1

United States